Search results
Results from the WOW.Com Content Network
Cerebrospinal fluid rhinorrhoea; Specialty: Neurology, neurosurgery, otorhinolaryngology,Oral and maxillofacial surgery: Symptoms: clear, colourless liquid draining from nose: Complications: infection: Causes: basilar skull fracture: Diagnostic method: brain scans, testing nasal discharge to see if it is CSF: Differential diagnosis: other types ...
Xanthochromia, from the Greek xanthos (ξανθός) "yellow" and chroma (χρώμα) "colour", is the yellowish appearance of cerebrospinal fluid that occurs several hours after bleeding into the subarachnoid space caused by certain medical conditions, most commonly subarachnoid hemorrhage. [1]
Diagnosis of CSF leakage can be done by various imaging techniques, chemical tests of bodily fluid discharged from a head orifice, or clinical examination. The use of CT, MRI, and assays are the most common types of CSF leak instrumental tests. Many CSF leaks do not show up on imaging and chemical assays, thus such diagnostic tools are not ...
The doctor can look for potential underlying causes, including dementia, medication effects, or environmental factors, Elhelou says. From there, they can suggest effective ways to help you manage ...
Frontotemporal dementia (FTD) is an early onset disorder that mostly occurs between the ages of 45 and 65, [13] but can begin earlier, and in 20–25% of cases onset is later. [11] [14] Men and women appear to be equally affected. [15] It is the most common early presenting dementia. [16]
This isn’t the first time that better sleep has been linked with a lower risk of dementia: A study published in October even found that people with sleep apnea are more likely to develop dementia.
Millions of Americans are at risk of developing dementia, but early detection and proactive measures could help delay its onset and mitigate its effects, according to a new report.
ARIA-E refers to cerebral edema, involving the breakdown of the tight endothelial junctions of the blood-brain barrier and subsequent accumulation of fluid. [3] In a double-blind trial of the humanised monoclonal antibody solanezumab (n = 2042), sixteen patients (11 taking the drug, 5 taking a placebo), or 0.78% developed ARIA-E.